Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy Reardon DA; Wen PY; Desjardins A; Batchelor TT; Vredenburgh JJExpert Opin Biol Ther 2008[Apr]; 8 (4): 541-53BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors. OBJECTIVE: To summarize the clinical experience of VEGF-directed treatment for malignant glioma. METHODS: We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients. RESULTS/CONCLUSIONS: Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.|Adult[MESH]|Angiogenesis Inhibitors/adverse effects/*therapeutic use[MESH]|Antineoplastic Agents/adverse effects/*therapeutic use[MESH]|Central Nervous System Neoplasms/blood supply/*drug therapy/metabolism/pathology[MESH]|Clinical Trials as Topic[MESH]|Female[MESH]|Glioblastoma/blood supply/*drug therapy/metabolism/pathology[MESH]|Humans[MESH]|Male[MESH]|Middle Aged[MESH]|Neovascularization, Pathologic/*drug therapy/metabolism[MESH]|Signal Transduction/drug effects[MESH]|Treatment Outcome[MESH]|Vascular Endothelial Growth Factor A/*antagonists & inhibitors/metabolism[MESH] |